Sanofi: new positive data for Beyfortus

(CercleFinance.com) - Sanofi announces that its Beyfortus vaccine reduced the risk of hospitalization due to respiratory syncytial virus (RSV) by 82% in infants under six months of age, compared with those who had not been immunized against RSV.


These positive data, published in The Lancet, are the interim results of the ongoing NIRSE-GAL study, a three-year study conducted in Galicia. They correspond to the first season of RSV circulation since the introduction of Beyfortus.

These results confirm the data obtained in pivotal clinical studies and the phase IIIb HARMONIE clinical trial, conducted under conditions close to real life, which demonstrated the high efficacy of Beyfortus.

Copyright (c) 2024 CercleFinance.com. All rights reserved.